American Head and Neck Society Alando J. Ballantyne Resident Research Pilot Grant
For the best grant application by a resident in the U.S. or Canada. One year, non-renewable, $10,000, one available annually.
The purpose of this award is to support basic, translational, or clinical research projects in head and neckoncology. Clinical or translational research studies are strongly encouraged and should be specificallyrelated to the prevention, diagnosis, treatment, outcomes, or pathophysiology of head and neckneoplastic disease. The Alando J. Ballantyne Resident Research Pilot Grant memorializes Alando J.Ballantyne, M.D., a giving teacher, dedicated surgeon, and a devoted husband and father.ELIGIBILITYThis grant is open to resident in U.S. or Canadian training programs. Previous AHNS or AAO-HNSFoundation research grant recipients are eligible to compete for this grant. However, candidates whohave successfully obtained funding from a private or federal funding agency for the same research areineligible. Candidates who have applied for support of the same research from other funding sources, andwho are notified of an award from both another agency and from AHNS must choose only one of theawards.CONDITIONSResearch supported by this award should be specifically directed toward the pathogenesis,pathophysiology, diagnosis, prevention, or treatment of head and neck neoplastic disease, and may beeither basic or clinical/translational in approach. While not specifically required, proposals which aim tointroduce new knowledge and methodology from other disciplines to research in head and neck disease,or which demonstrate collaborative effort with members of other related disciplines are encouraged.Projects must be designed so as to yield useful information within the period of award, but priority will begiven to projects that are also innovative with promise to develop into new long-range or expandedresearch programs capable of attracting funding from other sources. The grant application must beaccompanied by letters of support from the Chair of the candidate’s academic department and from theprincipal scientific advisor or mentor. These letters are to indicate a general level of support of theapplicant, the fact that the Department will make time, space, and other resources accessible forcompletion of the project, and that the applicant will have appropriate supervision/support throughout theperiod of the grant. Applicants must obtain letters of support/understanding from all key personnel on theproject.TERMS1. Amount: $10,000 maximum2. Period: 12 months, non-renewable
All applicants must submit a Letter of Intent online no later than midnight Eastern Standard TimeDecember 15. The letter of intent includes the title of the project, the principal investigator, and anabstract of the work. This will facilitate planning review requirements.
American Head and Neck Society Pilot Grant
Open to Medical Students, residents, PhD, and junior faculty residing in the U.S. and Canada to support basic, translational, or clinical research projects in head and neck oncology. One year, $10,000, one available annually.
The purpose of this award is to support basic, translational, or clinical research projects in head and neckoncology. Clinical or translational research studies are strongly encouraged and should be specificallyrelated to the prevention, diagnosis, treatment, outcomes, or pathophysiology of head and neckneoplastic disease.ELIGIBILITYCandidates for this award should reside in the U.S. or Canada, be medical students, residents, Ph.D.s orfaculty members at the rank of associate professor or below. Previous AHNS or AAO-HNS Foundationresearch grant recipients are eligible to compete for this grant. However, candidates who havesuccessfully obtained funding from a private or federal funding agency for the same research areineligible. Candidates who have applied for support of the same research from other funding sources, andwho are notified of an award from both another agency and from AHNS must choose only one of theawards.CONDITIONSResearch supported by this award should be specifically directed toward the pathogenesis,pathophysiology, diagnosis, prevention, or treatment of head and neck neoplastic disease, and may beeither basic or clinical/translational in approach. While not specifically required, proposals which aim tointroduce new knowledge and methodology from other disciplines to research in head and neck disease,or which demonstrate collaborative effort with members of other related disciplines are encouraged.Projects must be designed so as to yield useful information within the period of award, but priority will begiven to projects that are also innovative with promise to develop into new long-range or expandedresearch programs capable of attracting funding from other sources.The grant application must be accompanied by letters of support from the Chair of the candidate’sacademic department and from the principal scientific advisor or mentor. These letters are to indicate ageneral level of support of the applicant, the fact that the Department will make time, space, and otherresources accessible for completion of the project, and that the applicant will have appropriatesupervision/support throughout the period of the grant. Applicants must obtain letters ofsupport/understanding from all key personnel on the project.TERMS1. Amount: $10,000 maximum2. Period: One year, non-renewable
UICC Yamagiwa-Yoshida Memorial international study grants Target candidates Investigators, clinicians, epidemiologists, public health professionals Duration 3 months Extension Up to 3 months with funding secured by the Fellow from other sources and at no cost to UICC Available 14-16 per year Average value US$10,000 each Application closing dates 15 January and 1 July Notification of result April and October Note: This is not a clinical training fellowship Objectives to initiate, set up or pursue bilateral cancer research projects with collaborating investigators abroad to exchange and exploit complementary skills and material to receive training in advanced experimental research methods and techniques
Profile of eligible candidates appropriate scientific or medical qualifications and a minimum of two years postdoctoral experience active engagement in cancer research recent publications in the international peer-reviewed literature
Research plan basic, translational or applied cancer research Prevention-oriented projects are especially encouraged Twice-yearly competitive selections are conducted by an international panel of experts based on the scientific evaluation of the research plan the experience and qualifications of the candidate the suitability of the host organization and host supervisor
appropriate duration the availability of appropriate facilities and resources to apply and disseminate the acquired skills upon return to the home organization
To contact UICC, write to us at the following address: International Union Against Cancer (UICC) 62 route de Frontenex 1207 Geneva, Switzerland Telephone +41 22 809 1811 Fax +41 22 809 1810
Oncology Nursing Society Foundation Cancer Public Education Project Grant Awards: Up to $5,000 available for funding. Purpose: To enhance the public's knowledge and awareness of cancer prevention, detection, and treatment modalities. Selection Criteria: The candidate must have a current license to practice as a registered nurse and must have an interest in and commitment to oncology nursing. The major focus of the project should be some aspect of cancer public education. Application deadline: December 1, 2008
ONS Foundation 125 Enterprise Drive Pittsburgh, PA 15275 866-257-4ONS 412-859-6100 877-369-5497 (toll free fax) 412-859-6163 (fax) E-mail: foundation@ons.org Web site: www.onsfoundation.org
AACR Award for Outstanding Achievement in Chemistry in Cancer Research Nominations for the 2009 Award will open in September 2008. Nomination deadline: Wednesday, October 15, 2008 The Award & Lecture The AACR and its Chemistry in Cancer Research Working Group established this Award in 2007 to recognize the importance of chemistry to advancements in cancer research. The Award will be given for outstanding, novel, and significant chemistry research, which has led to important contributions to the fields of basic cancer research; translational cancer research; cancer diagnosis; the prevention of cancer; or the treatment of patients with cancer. Such research may include, but is not limited to, drug discovery and design; structural biology; proteomics, metabolomics and biological mass spectrometry; chemical aspects of carcinogenesis; imaging agents and radiotherapeutics; and chemical biology. The winner of the 3rd Annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research will give a 50-minute lecture during the AACR Annual Meeting 2009 in Denver, CO, USA (April 18-22, 2009), and will receive a commemorative plaque and $10,000 honorarium. Eligibility Criteria Candidacy is open to all researchers who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry, or government. The Award will be presented to an individual investigator. Two or more individuals may be selected to share the Award when their investigations are closed related in subject matter and have resulted in work worthy of an award. Institutions or organizations are not eligible for the Award. Selection of the Award winner will be made on the outstanding quality, novelty, and significance of the candidates' chemistry research and its important contributions to cancer research. No regard will be given to race, gender, nationality, geographic location, or religious or political views. Prior recipients of the AACR-Bruce F. Cain Memorial Award are not eligible to be nominated for research previously recognized by the Cain Award. Nomination Process Nominations may be made via letter from any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science. Candidates may not nominate themselves. Nomination letters must be sent electronically to the AACR by Wednesday, October 15, 2008 at 4:00 p.m., United States Eastern Time. Preferred file formats are *.doc, *.pdf. Your nomination is not considered fully submitted until you receive a confirmation e-mail from the AACR; confirmations will be sent within 2 business days. The nomination letter must be addressed to the Selection Committee; be written in English; and not exceed 1,000 words. The content should include the following:
the name of the AACR Award for which the candidate is being nominated; a brief statement of no more than 50-words summarizing the candidate's cancer research accomplishment(s) for which he or she is being nominated; a concise description of the candidate's outstanding cancer research accomplishments in the fields of epidemiology, biomarkers, and prevention, with the publications supporting these accomplishments directly referenced within the letter; and a concise description of the impact of these accomplishments on the field. Nominators are asked to maintain the confidentiality of the nomination process and to refrain from informing the candidate about the nomination. There is no restriction on the number of candidates that may be nominated by any individual scientist. There is no restriction on the number of nominators that may write nomination letters or that may sign a single nomination letter on behalf of a candidate. Selection Candidates will be considered by a Selection Committee of international cancer leaders appointed by the President of the AACR. The Committee will consider all nominations as they have been submitted; the Committee may not combine submitted nominations, add a new candidate to a submitted nomination, or otherwise make alterations to the submitted nominations. After careful deliberations by the Committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the Award winner will be made on the basis of the candidate's outstanding, novel, and significant chemistry research related to cancer. No regard will be given to age, race, gender, nationality, geographic location, or religious or political views. The winner of the 3rd Annual AACR-CICR Award will be announced in January 2009. Supporter Generously supported by GlaxoSmithKline. Questions? Monique P. Eversley, Program Associate +1 (267) 646-0576; monique.eversley@aacr.org American Association for Cancer Research 17th Floor, 615 Chestnut Street Philadelphia, PA 19106-4404
AACR Princess Takamatsu Memorial Lectureship
The Lectureship The AACR Princess Takamatsu Memorial Lectureship was established and first presented in 2007 in honor of the late Princess Takamatsu of Japan. During her extraordinary life, Her Imperial Highness Princess Takamatsu expended tremendous efforts toward the public and humanitarian cause of the eradication of cancer. She is regarded as an honored and respected figure in Japan, the United States, and within the international cancer research community as a whole. This Lectureship will recognize an individual scientist whose novel and significant work has had or may have a far-reaching impact on the detection, diagnosis, treatment, or prevention of cancer, and who embodies the dedication of the Princess to multinational collaborations. The recipient of the 2nd Annual Lectureship will present a major, 50-minute lecture during the AACR Annual Meeting 2009 in Denver, CO, USA (April 18-22, 2009). The Lecturer will receive an unrestricted cash award of US$10,000, support to attend the AACR Annual Meeting, and a commemorative item serving as tangible witness to the singular honor of his/her selection. Eligibility Criteria Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry, or government. The Lectureship will be presented to an individual investigator. Institutions or organizations are not eligible for the Lectureship. Nomination Process Nominations for the Lectureship must be submitted electronically to awards@aacr.org no later than 4:00 p.m. US Eastern Time on October 15, 2008. Paper nominations will not be accepted. Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science. Candidates may not nominate themselves. Nominators are asked to maintain the confidentiality of the nomination process and to refrain from informing the candidate about the nomination. There is no restriction on the number of candidates nominated by any institution or nominator. Nomination Materials The following materials must be sent electronically to the AACR as noted above. Preferred file formats are *.doc, *.pdf. Your nomination is not considered fully submitted until you receive a confirmation e-mail from the AACR; confirmations will be sent within 2 business days. 1) Letter of Recommendation. The letter of recommendation must: be addressed to the Selection Committee; be written in English; and not exceed 1,000 words; specify the AACR Lectureship for which the candidate is being nominated; and describe the candidate's novel and significant work in cancer research and dedication to multinational collaborations, with the publications supporting these accomplishments directly referenced within the letter. 2) Candidate's CV. The candidate's curriculum vitae in English, including a complete list of the candidate's publications. 3) Summary Statement. A statement of no more than 50 words summarizing the candidate's accomplishments for which he or she is being nominated. Selection Candidates will be considered by a Selection Committee of international cancer leaders appointed by the President of the AACR. Selection of the Lecturer will be made on the basis of the novel and significant work, its far-reaching impact on the detection, diagnosis, treatment, or prevention of cancer, and his or her embodiment of the dedication of the Princess to multinational collaborations. No regard will be given to age, race, gender, nationality, geographic location, or religious or political views. After careful deliberations by the Committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Supporter Generously supported by Princess Takamatsu Cancer Research Foundation (Japan). Questions? Monique P. Eversley, Program Associate +1 (267) 646-0576; monique.eversley@aacr.org American Association for Cancer Research 17th Floor, 615 Chestnut Street Philadelphia, PA 19106-4404
American Society of Clinical Oncology Cancer Foundation Young Investigator Award The Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this award is to fund physicians during the transition from a fellowship program to a faculty appointment. Priority consideration will be given to proposals that include patient-oriented and, ultimately, clinical research. Since many awards are supported with restricted grants from outside organizations, we are particularly interested in identifying young researchers working in the following subspecialties and emerging disciplines: Breast Cancer Cancer Survivorship Geriatric Oncology Health Disparities Kidney Cancer Multiple Myeloma Ovarian Cancer Pancreatic Cancer Sarcoma Survivorship Young Adult Cancer However, The ASCO Cancer Foundation welcomes application submissions in all oncology subspecialties. The 2009 online applications are now open! APPLY NOW for the 2009 PROGRAM Online Applications will close at 5:00 pm (EST) on October 30, 2008. If you have any questions, please contact grants@asco.org.
Mission The Young Investigator Award is intended to support proposals with a clinical research focus. ASCO’s definition of clinical research is “hypothesis-driven research that employs measurements in whole patients or normal human subjects, in conjunction with laboratory measurements as appropriate, on the subjects of clinical biology, natural history, prevention, screening, diagnosis, therapy, or epidemiology of neoplastic disease” (Journal of Clinical Oncology, Vol. 14, No. 2, 1996 pp. 666-670). In Young Investigator Award proposals, preclinical in vitro +/- animal studies are acceptable as long as the outcome of these studies would ultimately lead to patient-oriented clinical research.
Eligibility The recipient must be a physician (MD or DO) who, at the time of grant award (July 2009), is in the final year of his/her final subspecialty training program or in the first year post his/her final subspecialty training An institutional commitment for a faculty appointment at the time of grant submission is not required, but the applicant should be working in an oncology laboratory or clinical research setting The sponsoring facility must be an academic medical institution. The primary mentor must be in the candidate’s proposed research field, and must assume responsibility and provide guidance for the research. If the mentor is not an active ASCO member, a supporting letter from an ASCO member must be included Applicants should be planning an investigative career in clinical oncology The applicant must either be a member of ASCO or submit a membership application with the grant application The applicant should spend at least 60 – 75% of his/her time in research during the award period An MD, PhD is eligible if the terminal degree is completed prior to the start of the grant period Eligible physicians may submit only one application to The ASCO Cancer Foundation per year The ASCO Cancer Foundation Grants Selection Committee reserves the right to evaluate and determine applicants’ eligibility based on the information and justifications included in the application materials.
Award Term The award is for a one-year period, July 1, 2009 – June 30, 2010, for a total amount of $50,000. Payments are made to the applicant’s institution in two equal installments on July 1 and January 1. The award is comprised of $46,000 to support the grant project, $1,500 for travel related to the project, including the ASCO Annual Meeting, and $2,500 for the institution to help defray costs related to the administration of the project.
American Society of Clinical Oncology Cancer Foundation Career Development Award
The Career Development Award (CDA) provides funding to clinical investigators who have received their initial faculty appointment to establish an independent clinical cancer research program. Since many awards are supported with restricted grants from outside organizations, we are particularly interested in identifying young researchers working in the following subspecialties and emerging disciplines: Breast Cancer Cancer Survivorship Geriatric Oncology Health Disparities Kidney Cancer Multiple Myeloma Ovarian Cancer Pancreatic Cancer Sarcoma Survivorship Young Adult Cancer However, The ASCO Cancer Foundation welcomes application submissions in all oncology subspecialties. The 2009 online applications are now open! APPLY NOW for the 2009 PROGRAM Online Applications will close at 5:00 pm (EST) on October 30, 2008. If you have any questions, please contact grants@asco.org.
Mission The Career Development Award is intended to support proposals with a clinical research focus. ASCO’s definition of clinical research is "hypothesis-driven research that employs measurements in whole patients or normal human subjects, in conjunction with laboratory measurements as appropriate, on the subjects of clinical biology, natural history, prevention, screening, diagnosis, therapy, or epidemiology of neoplastic disease” (Journal of Clinical Oncology, Vol. 14, No. 2, 1996 pp. 666-670). Proposals must have a patient-oriented focus including a clinical research study involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed.
EligibilityAt the time of the grant award (July 2009), the applicant must meet the following criteria: Be a physician (MD, DO, or international equivalent with explanation) Be in the second, third or fourth year of a full-time, primary faculty appointment in a clinical department at an academic medical institution Have completed his/her final subspecialty training within the past four years. Special considerations are allowed (such as military service, family leave, etc) if written justification is included in the application. Have an institutional commitment as a faculty member in a clinical oncology program Have completed productive postdoctoral research and demonstrated the ability to undertake independent investigator-initiated clinical research Be a member of ASCO or submit a membership application with the grant application Spend more than 50% of his/her time in research during the award period Have a mentor from his/her institution and provide an institutional letter of support. If the mentor is not an active ASCO member, a supporting letter from an active ASCO member must be included. Eligible physicians may submit only one application to The ASCO Cancer Foundation per year Applicants with existing career development awards (such as a K23, K08, or any other type of career development award) will not be considered for funding The ASCO Cancer Foundation Grants Selection Committee reserves the right to evaluate and determine applicants' eligibility based on the information and justifications included in the application materials.
Award Terms The total award amount is $200,000 paid in three annual increments of $66,666 on July 1. The award is comprised of $59,966 per year for support of the project, $2,500 per year for travel including the ASCO Annual Meeting, and $4,200 per year for the institution to help defray its costs related to the administration of the project. The award period begins July 1, 2009 and concludes June 30, 2012.
12next
